AnnualReports.com – the leading provider of online annual reports to individual and institutional investors.

Targacept, Inc.


Targacept, Inc., a biopharmaceutical company, engages in the discovery, design, and development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of diseases and disorders of the nervous system. Its products include TC-5214, a nicotinic channel modulator, which is in Phase III clinical trials as an adjunct treatment for depressive disorder; and in Phase IIb clinical trial for switch monotherapy in patients with depressive disorder.

View Online Reports: Order Free Hardcopy You can request a free hardcopy of this report mailed to you by clicking the button below.
Add Annual Report

No investor fact sheets added yet
No responsibility reports added yet

Browse Reports